Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ospemifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 12/20 | 0.70 |
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HTR6 | P50406 | 1/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | ESRRG | P62508 | 14/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ESRRB | O95718 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ospemifene SCHEMBL948120 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| Ospemifene SCHEMBL948118 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5737939 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362664 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362668 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373604 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362672 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373608 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5738281 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5738276 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056701-B1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORP (FI) | 2003-10-22 | — | — | EP | claimed |
| US-6395785-B1 | ANTICHOLESTEROL AGENTS; HORMONE REPLACEMENT THERAPY | ORION CORPORATION (FI) | 2002-05-28 | — | — | US | claimed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | claimed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | claimed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9085519-B2 | Processes for producing benzophenone derivatives | CAMBREX KARLSKOGA AB (SE) | 2015-07-21 | — | — | US | disclosed |
| EP-2526080-B1 | NEW PROCESSES FOR PRODUCING BENZOPHENONE DERIVATIVES | CAMBREX KARLSKOGA AB (SE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035514-A1 | NEW PROCESSES FOR PRODUCING BENZOPHENONE DERIVATIVES | CAMBREX KARLSKOGA AB (SE) | 2013-02-07 | — | — | US | disclosed |
| EP-2526080-A1 | NEW PROCESSES FOR PRODUCING BENZOPHENONE DERIVATIVES | Cambrex Karlskoga AB (SE) | 2012-11-28 | — | — | EP | disclosed |
| WO-2011089385-A1 | NEW PROCESSES FOR PRODUCING BENZOPHENONE DERIVATIVES | CAMBREX KARLSKOGA AB (SE) | 2011-07-28 | — | — | WO | disclosed |
| CN-1161314-C | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof | ���ŷ� | 2004-08-11 | — | — | CN | disclosed |
| CN-1161314-C | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof | ���ŷ� | 2004-08-11 | — | — | CN | disclosed |
| CN-1291178-A | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof | ORION CORP (FI) | 2001-04-11 | — | — | CN | disclosed |
| CN-1291178-A | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof | ORION CORP (FI) | 2001-04-11 | — | — | CN | disclosed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035514-A1 | NEW PROCESSES FOR PRODUCING BENZOPHENONE DERIVATIVES | CYP1B1, CYP4B1, CYP2B6 | ESR1 313/4885ESR2 495/4885LMNA 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.